About Cluster Headache

Cluster Headache is considered one of the most severe primary headache forms1

Cluster headache belongs to the group of primary headache disorders called trigeminal autonomic cephalalgias2

There are 2 types of cluster headache2,3:

Percentage of cluster headache patients pie chart

aEmgality (galcanezumab-gnlm) is not indicated for the treatment of chronic cluster headache.4

It has been shown that patients with episodic cluster headache experience an average of ~2 active cluster periods per year, each lasting an average of ~8 weeks5

Attacks stopwatch image. Attacks last 15 to 180 minutes and can occur from once every other day to 8 times a day<sup>2,5</sup>

Pain and associated symptoms of cluster headache2

Cluster headache is characterized by severe to very severe pain on 1 side of the head2

Pain is felt in the orbital, supraorbital, and/or temporal regions and is accompanied by either or both of the following2:

1. At least 1 of the following symptoms or signs, ipsilateral to the headache:

Eye symptoms icon
Nasal symptoms icon
Eyelid symptoms icon
Facial symptoms icon
Eyelid symptoms icon


2. And/or:

Restlessness icon


Cluster headache is a debilitating disease that is under-recognized and misdiagnosed in many cases2,6-9

Many patients go years without appropriate treatment due to delayed diagnosis7,9

In a US survey of 1134 individuals with cluster headache10:

21% of responders

Only 21% of responders reported receiving a correct diagnosis of cluster headache at initial diagnosis

42% of responders

42% of responders reported that it took 5 years or longer from symptom onset to receive a correct diagnosis

Indications and Important Safety Information

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.